What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression
The DOI matches its Crossref record.
Abstract
The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms do not remit or who cannot tolerate an initial treatment and, if needed, ensuing treatments. Entry criteria were broadly defined and inclusive, and patients were enrolled from psychiatric and primary care clinics. All participants began on citalopram and were managed by clinic physicians, who followed an algorithm-guided acute-phase treatment through five visits over 12 weeks. At the end of each sequence, patients whose depression had not fully remitted were eligible for subsequent randomized trials in a sequence of up to three clinical trials. In general, remission rates in the study clinics were lower than expected, suggesting the need for several steps to achieve remission for most patients. There was no clear medication "winner" for patients whose depression did not remit after one or more aggressive medication trials. Both switching and augmenting appeared to be reasonable options when an initial antidepressant treatment failed, although these two strategies could not be directly compared. Further, the likelihood of remission after two vigorous medication trials substantially decreased, and remission would likely require more complicated medication regimens for which the existing evidence base is quite thin. STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative. Policy implications of the findings, as well as the study's limitations, are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“low efficacy (only 27% of depressed patients achieved remission after 12 weeks of citalopram treatment as measured by HAM-D)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [259]
In the citing paper
“the current standard of care treatments suffer from slow onset (e.g., 7 week average response time with citalopram)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [259]
In the citing paper
“Studies examining antidepressant efficacy reveal 30% of depressed patients fail to respond to common antidepressant treatment (1)”
From Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression (2017) · cites this paper as [1]
In the citing paper
“Currently available antidepressant medications, alone and in combination, are associated with high rates of partial- or non-response, delayed response onset of weeks to months, and limited duration of efficacy5.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [5]
In the citing paper
“while more than a third fail to achieve remission even after several rounds of treatment ( Al-Harbi, 2012 , Gaynes et al., 2009 , Strawbridge et al., 2022 )”
From Self-blame-selective hyper-connectivity between anterior temporal and subgenual cortices predicts prognosis in major depressive disorder (2023) · cites this paper as Gaynes et al., 2009
Citations
Cites
Still being checked.
Cited by
Items 401–500 of 764
What fMRI studies say about the nature of the psychedelic effect: a scoping review
Beneš, M., Páleníček, T., & Horáček, J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1606798 · Cited by 10
Apostol, M., Valles, T. E., Corlier, J., Leuchter, M. K., Young, A. S., Artin, H., Koek, R. J., Einstein, E. H., Wilke, S. A., Tadayonnejad, R., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121345 · Cited by 9
Liao, Y.-L., Wang, P.-S., Lu, C.-F., Hung, C., Li, C., Lin, C., Hsieh, J., Su, T., & Wu, Y.-T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068625 · Cited by 9
Bonetto, G. G., Corral, R. M., Lupo, C., Vilapriño, M., Alessandria, H., KANEVSKY, G. A., & Cabrera, P. (2022) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v33i155.134 · Cited by 10
Hippocampal subfield volumes in treatment resistant depression and serial ketamine treatment
Zavaliangos‐Petropulu, A., McClintock, S. M., Joshi, S. H., Taraku, B., Al‐Sharif, N., Espinoza, R. T., & Narr, K. L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1227879 · Cited by 9
Oliveira-Maia, A. J., Rive, B., Morrens, J., Godinov, Y., Cabrieto, J., Perualila, N. J., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250987 · Cited by 9
Montano, C. B., Jackson, W. C., Vanacore, D., & Weisler, R. H. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s337703 · Cited by 9
Bayesian network analysis of antidepressant treatment trajectories
Turner, R., Hagoort, K., Meijer, R. J., Coenen, F., & Scheepers, F. E. (2023) · Scientific Reports · doi:10.1038/s41598-023-35508-7 · Cited by 10
Liu, X., & Read, S. J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1349576 · Cited by 9
Rajkumar, R. P. (2024) · Brain Sciences · doi:10.3390/brainsci14060543 · Cited by 9
Chen, Y., Shen, M., Liu, X., Xu, J., & Wang, C. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.789524 · Cited by 9
Söderholm, J. J., Socada, J. L., Rosenström, T. H., Ekelund, J., & Isometsä, E. T. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.030 · Cited by 9
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Trueman, H., de Boer, M. K., Schoevers, R. A., & McShane, R. H. (2018) · BJPsych Open · doi:10.1192/bjo.2018.51 · Cited by 9
Predict Risk of Relapse for Patients with Multiple Stages of Treatment of Depression
Nie, Z., Gong, P., & Ye, J. (2016) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/2939672.2939870 · Cited by 9
Methoxetamine: A foe or friend?
Botanas, C. J., de la Peña, J. B., Kim, H. J., Lee, Y. S., & Cheong, J. H. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.10.020 · Cited by 9
Psychiatric pharmacogenomics in the age of neuroscience: promises and challenges
Köse, S., & Çetin, M. (2018) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2018.1518191 · Cited by 9
Rosenblat, J. D., Simon, G. E., Sachs, G. S., Deetz, I., Doederlein, A., DePeralta, D., Dean, M. M., & McIntyre, R. S. (2018) · Annals of Clinical Psychiatry · doi:10.1177/104012371803000407 · Cited by 8
Kauffman, K., Dolata, J., Figueroa, M., Gunzler, D. D., Huml, A. M., Pencak, J. A., Sajatovic, M., & Sehgal, A. R. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100413 · Cited by 8
Role of Pharmacogenomics in Comprehensive Medication Management: Considerations for Employers
Fragala, M. S., Shaman, J. A., Lorenz, R. A., & Goldberg, S. E. (2022) · Population Health Management · doi:10.1089/pop.2022.0075 · Cited by 8
Salari, M., Eftekhar‐Vaghefi, S. H., Asadi‐Shekaari, M., Esmaeilpour, K., Solhjou, S., Amiri, M., & Ahmadi‐Zeidabadi, M. (2023) · Brain and Behavior · doi:10.1002/brb3.2986 · Cited by 8
Individualized Treatment Strategy for Depressive Disorder
Chen, J., & Hu, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9271-0_12 · Cited by 9
Reinforcement Learning in Neurocritical and Neurosurgical Care: Principles and Possible Applications
Liu, Y., Qiao, N., & Altınel, Y. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/6657119 · Cited by 8
Asakura, S., Koyama, T., Hosokai, T., Kawano, H., & Kajii, Y. (2014) · Drugs - Real World Outcomes · doi:10.1007/s40801-014-0005-2 · Cited by 8
Dayan, S. H. (2015) · Aesthetic Surgery Journal · doi:10.1093/asj/sjv032 · Cited by 8
Carboni, L., Nguyen, T., & Caberlotto, L. (2016) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500149 · Cited by 8
Well-being Therapy in Depressive Disorders
Mansueto, G., & Cosci, F. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_19 · Cited by 8
Fennema, D., Barker, G. J., O'Daly, O., Duan, S., Carr, E., Goldsmith, K., Young, A. H., Moll, J., & Zahn, R. (2023) · NeuroImage: Clinical · doi:10.1016/j.nicl.2023.103453 · Cited by 7
“, 2013), while more than a third fail to achieve remission even after several rounds of treatment (Al-Harbi, 2012; Gaynes et al., 2009; Strawbridge et al., 2022).”
BackgroundBærentzen, S. L., Waszkiewicz, A. L., Thomsen, M., Knudsen, C., Elfving, B., & Landau, A. M. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104079 · Cited by 7
“…pharmacological treatments have a late onset of 3 – 6 weeks, and there is limited to no effect in 30% of MDD patients who are classified with treatment-resistant depression (TRD) after having failed to respond to two or more conventional antidepressants (Gaynes et al., 2009; Gaynes et al., 2020).”
Shao, Q., Li, Y., Jin, L., Zhou, S., Fu, X., Liu, T., Luo, G., Du, S., & Chen, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1491900 · Cited by 7
Wade, B., Pindale, R., Luccarelli, J., Li, S., Meisner, R. C., Seiner, S. J., Camprodon, J. A., & Henry, M. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01523-3 · Cited by 7
Polygenic dissection of treatment-resistant depression with proxy phenotypes in the UK Biobank
Wang, L.-H., Shih, M.-Y., Lin, K., Kuo, P., & Feng, Y. A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.012 · Cited by 7
Troppoli, T. A., & Thompson, S. M. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.10.036 · Cited by 7
Do we need more than one antidepressant for patients with major depressive disorder?
Pae, C., Han, C., & Jun, T. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.150 · Cited by 7
Huang, W., Chiang, C. N., Wu, C., Liao, S., Chien, T. H., Tseng, C.-H., & Tang, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.114 · Cited by 7
Serum L-selectin levels as predictive markers for chronic major depressive disorder progression
Yun, Y., Mun, S., Lee, S., Kang, H., & Lee, J. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00522-0 · Cited by 7
Behavioral Health Treatment and Police Officer Safety
Deza, M., Lu, T. T., Maclean, J. C., & Ortega, A. (2023) · The Journal of Human Resources · doi:10.3368/jhr.1223-13303r3 · Cited by 7
CBT for treatment resistant depression
Otto, M. W., & Wisniewski, S. R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61844-3 · Cited by 7
Self-citationDissociating the Clinical Role and Economic Value of Intranasal Esketamine
Dadiomov, D. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.1.20 · Cited by 7
Crutchley, R. D., & Keuler, N. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884213 · Cited by 7
Ramaraj, R., Al-Mahayri, Z. N., Saleous, R., Aziz, K. A., Mugaddam, F. A., Al-Sabousi, M., Alhassani, A., Ahbabi, N. A. A., Stip, É., Patrinos, G. P., et al. (2023) · Psychiatric Quarterly · doi:10.1007/s11126-023-10044-9 · Cited by 7
Oliveira-Maia, A. J., Morrens, J., Rive, B., Godinov, Y., Cabrieto, J., Perualila, N. J., Barbreau, S., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250980 · Cited by 7
Widge, A. S., Ellard, K. K., Paulk, A. C., Basu, I., Yousefi, A., Zorowitz, S., Gilmour, A., Afzal, A., Deckersbach, T., Cash, S. S., et al. (2022) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20102 · Cited by 7
Han, C., Wang, S., Bahk, W., Lee, S.-J., Patkar, A. A., Masand, P. S., Mandelli, L., Pae, C., & Serretti, A. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.4.641 · Cited by 7
Su, T., Chen, M., Li, C., Lin, W., Hong, C., Gueorguieva, R. V., Tu, P., Bai, Y., Cheng, C., & Krystal, J. H. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0253-z · Cited by 7
Treatment for Mental Health and Substance Use: Spillovers to Police Safety
Deza, M., Lu, T. T., Maclean, J. C., & Ortega, A. (2023) · National Bureau of Economic Research · doi:10.3386/w31391 · Cited by 7
Efficacy of Minocycline in Depression: A Systematic Review and Meta-analysis
Huang, H., Zou, Z., & Chen, B. (2025) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000618 · Cited by 5
Becker-Sadzio, J., Brendel, B., Weller, S., Bornheimer, E., Mehlig, U., Padberg, F., Vogelmann, U., Kammer, T., Strube, W., Martus, P., et al. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-01975-4 · Cited by 6
Chronopharmacokinetics of the antidepressant paroxetine: An in vitro and in vivo approach
Silva, S., Bicker, J., Falcão, A. C., Dallmann, R., & Fortuna, A. C. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110441 · Cited by 6
A brain-enriched circRNA blood biomarker can predict response to SSRI antidepressants
Papageorgiou, G., Ibrahim, E. C., Gorgievski, V., Maxson, G., Lozano, E., Gordon, E., Lefrere, A., Toupet, M.-J., Courtet, P., Belzeaux-R, R., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03491-w · Cited by 6
Self-citationBarron, D. S., & Friedman, R. A. (2022) · Science Advances · doi:10.1126/sciadv.abp8283 · Cited by 6
Caldieraro, M. A., Tung, T. C., Baena, L. M. A., Vilapriño, M., Corral, R. M., de la Serna, L. D. A., Uribe, E. S., KANEVSKY, G. A., & Cabrera, P. (2022) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2022.06.002 · Cited by 6
Plasma levels of interleukin‐8 and response to paroxetine in patients with major depressive disorder
Guan, X., Dong, Z., Hao, Y., Shen, X., Xie, Q., & Chen, J. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2855 · Cited by 6
Barrutieta-Arberas, I., Ortuzar, N., Vaquero-Rodríguez, A., Picó-Gallardo, M., Bengoetxea, H., Guevara, M., Gargiulo, P. A., & Lafuente, J. V. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231170007 · Cited by 6
Siwek, M., Chrobak, A. A., Krupa, A. J., Gorostowicz, A., Gerlich, A., Juryk, A., & Dudek, D. (2023) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/174432 · Cited by 6
Wang, S., Kong, G., Wu, G., Cui, H., Qian, Z., Xu, L., Wei, Y., Wang, J., Huang, J., Wang, J., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-075525 · Cited by 6
Ketamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies
Averill, L. A., Murrough, J. W., & Abdallah, C. G. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_7 · Cited by 6
Adherence to augmentation therapy for the treatment of major depressive disorder
Forma, F. M., Liberman, J. N., Rui, P., & Ruetsch, C. R. (2023) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2167712 · Cited by 6
Ortiz, D. M., Kim, M., Lee, H. J., Botanas, C. J., Custodio, R. J. P., Sayson, L. V., Campomayor, N. B., Lee, C., Lee, Y. S., Cheong, J. H., et al. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.159 · Cited by 6
wei, L., Qi, X., Yu, X., Zheng, Y., Luo, X., Wei, Y., Ni, P., Zhao, L., Wang, Q., Ma, X., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115252 · Cited by 6
Bai, J., Ao, M., Xing, A., Yu, L.-J., Tong, H., Bao, W.-Y., & Wang, Y. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03855-1 · Cited by 6
Menon, V., Kale, A., Balasubramanian, I., & Andrade, C. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.103973 · Cited by 6
Wade, B., Sui, J., Njau, S. N., Leaver, A. M., Vasvada, M., Gutman, B. A., Thompson, P. M., Espinoza, R., Woods, R. P., Abbott, C., et al. (2017) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi.2017.7950570 · Cited by 6
The Current Crisis of Confidence in Antidepressants
(2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10035co1c · Cited by 6
Katayama, N., Nakagawa, A., Kurata, C., Sasaki, Y., Mitsuda, D., Nakao, S., Mizuno, S., Ozawa, M., Nakagawa, Y., Ishikawa, N., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-029735 · Cited by 6
Antidepressant adherence and its predictors in immigrants with depression: A population-based study
Jang, S., Cho, H., Kang, C., & Jang, S. (2020) · Medicine · doi:10.1097/md.0000000000023308 · Cited by 6
Mora, R., López, S. G., Villar, M., Palmer, R., & Perlado, B. R. (2016) · Psiquiatría Biológica · doi:10.1016/j.psiq.2016.11.002 · Cited by 6
Predicting Outcomes of Antidepressant Treatment in Community Practice Settings
Simon, G. E., Cruz, M., Boggs, J. M., Beck, A. L., Shortreed, S. M., & Coley, R. Y. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20230380 · Cited by 5
Slater, H. M., AlZubi, Y., Rezaeizadeh, A., Hughes, J. L., Gorman, A. R., Mayes, T., Elmore, J. S., Storch, E., Wakefield, S., & Trivedi, M. H. (2024) · Child Psychiatry and Human Development · doi:10.1007/s10578-023-01653-3 · Cited by 4
Self-citation5-HT1B receptor activation produces rapid antidepressant-like effects in rodents
Clark, E. A., Wang, L., Hanania, T., Kretschmannova, K., Bianchi, M., Jagger, E., Hu, T., Li, F., Gallero-Salas, Y., Koblan, K. S., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173917 · Cited by 5
Johnson, D. E., Rodrigues, N. B., Weisz, S., Chisamore, N., Kaczmarek, E. S., Chen-Li, D. C. J., Doyle, Z., Richardson, J. D., Mansur, R. B., McIntyre, R. S., et al. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.11.008 · Cited by 6
Jeffrey, J. K., Klomhaus, A., Aralis, H. J., Barrera, W., Rosenberg, S., Grossman, M., & Lester, P. E. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06729-1 · Cited by 5
Teng, C.-T., Caldieraro, M. A., Lacerda, A. L. T., Nardi, A. E., Quarantini, L. C., Souza, F., Corrêa, H., KANEVSKY, G. A., & Cabrera, P. (2021) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v13.n3.p310-21 · Cited by 5
Borgers, T., Zwiky, E., Klug, M., Enneking, V., Fisch, L., Klein, L., Neutz, L., Leehr, E. J., Opel, N., König, P., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.71 · Cited by 5
Is the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?
Ciftci, A., Ulaş, H., Topuzoǧlu, A., & Tunca, Z. (2015) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2015.10141 · Cited by 5
Therapeutic resistance in depression from the genetics and pharmacogenetics point of view
Mazo, G. E., Rukavishnikov, G. V., & Kibitov, A. O. (2019) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2019-4-1-43-47 · Cited by 5
Measurement-Based Care Implementation Challenges and Opportunities in Real-World Practice
Ridout, K. K., Vanderlip, E. R., Ridout, S. J., & Alter, C. L. (2023) · Psychiatric Annals · doi:10.3928/00485713-20230818-02 · Cited by 5
Kan, K., Feenstra, T., de Vries, S. O., Visser, E., Schoevers, R. A., & Jörg, F. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.010 · Cited by 5
Shoaib, M., Giacopuzzi, E., Pain, O., Fabbri, C., Magri, C., Minelli, A., Lewis, C. M., & Gennarelli, M. (2020) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-00186-5 · Cited by 5
Pérez-Morenilla, A., Salazar, A., Failde, I., González‐Sáiz, F., & Micó, J. A. (2025) · Psychiatry Research Communications · doi:10.1016/j.psycom.2025.100204 · Cited by 4
Zhang, X., Huang, M., Wangyang, X., Leiming, D., Yu, Y., & Zeng, J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120133 · Cited by 4
Arena, Á. R., Rubinstein, M. R., Genaro, A. M., Tifner, V., Risnik, D., López-Carvajal, J. E., Daray, F. M., Silva, E. A. C., & Errasti, A. E. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03338-w · Cited by 6
Jain, R. K., Laliberté, F., Germain, G., Mahendran, M., Higa, S., Harrington, A., & Parikh, M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.8.896 · Cited by 4
Ettore, É., Lindsay, H., Tröger, J., Balážia, M., Benoît, M., Robert, P. H., Postin, D., Hurlemann, R., & König, A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119769 · Cited by 4
Marek, G. J., Makai‐Bölöni, S., Umbricht, D., Christian, E. P., Winters, J., Dvořák, D., Raines, S. R., Hughes, Z. A., Austin, E. W., Klein, A. K., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251378512 · Cited by 4
Reddy, M., Abhilasha, P., Manikam, T., Ramanathan, R., & Kumar, S. (2021) · INDIAN JOURNAL OF MENTAL HEALTH AND NEUROSCIENCES · doi:10.32746/ijmhns.2019.v2.i1.10 · Cited by 4
Ferreira, F. R., Cupido, A., Cătălin, B., Silva, W. A., Kirchhoff, F., Bel, E. A. D., & Guimarães, F. S. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00334-0 · Cited by 4
Bailey, A. M., Barrett, A., Havens, L., Leyder, E. C., Merchant, T., Starnes, H. M., & Thompson, S. M. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114554 · Cited by 4
Ketamine for depressive symptoms: A retrospective chart review of a private ketamine clinic
Juby, V. M., Paruk, S., Tomita, M., & Chiliza, B. (2024) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v30i0.2176 · Cited by 4
Difficult to Treat Depression: Focus on Approach, Algorithms, and Access
Karp, J. F., Brinton, R. D., Fournier, J. C. J., Harding, L., Jha, M. K., Lenze, E. J., Mathew, S. J., Meltzer-Brody, S. E., Mohr, D. C., Riva‐Posse, P., et al. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.psprmdd2408ah · Cited by 5
Ionescu, D. F., Fava, M., Kim, D. J. H., Baer, L., Shelton, R. C., & Cusin, C. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315618621 · Cited by 4
Self-citationCusimano, J. M., & VandenBerg, A. (2020) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2020.100019 · Cited by 4
Fundamental Questions: Gender Dimensions in Max Planck Research Projects
Weber, U., & Verlagsgesellschaft, N. (2021) · Nomos Verlagsgesellschaft mbH & Co. KG eBooks · doi:10.5771/9783748924869 · Cited by 4
Katz, I. R., Liebmann, E. P., Resnick, S. G., Hoff, R. A., & Schmidt, E. M. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114797 · Cited by 4
Precision Medicine in Antidepressants Treatment
Tsermpini, E. E., Serretti, A., & Dolžan, V. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_654 · Cited by 4
Cha, D. S., Kleine, N., Teopiz, K. M., Vincenzo, J. D. D., Ho, R., Galibert, S. L., Samra, A., Zilm, S. P. M., Cha, R. H., d’Andrea, G., et al. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2298340 · Cited by 4
Antidepressant-Like Effects of Ketamine on Fear Conditioning and Extinction
Kulyk, B. D. (2017) · University Library - University of Saskatchewan (University of Saskatchewan) · Cited by 4
Seeking to Prevent Suicide at the Edge of the Ledge
Caine, E. D. (2019) · Annals of Internal Medicine · doi:10.7326/m19-2347 · Cited by 4
Cohen, J., Reichelt, A. C., Zamyadi, R., Roberts, G., Hardy, S., Fernandes, B., Rhind, S. G., Lewis, E. C., Bhat, V., Palner, M., et al. (2025) · medRxiv · doi:10.1101/2025.02.25.25322463 · Cited by 4
Taraku, B., Nomi, J. S., Zavaliangos‐Petropulu, A., Al‐Sharif, N., Pfeiffer, P., Norris, V., Joshi, S. H., Espinoza, R. T., Uddin, L. Q., & Narr, K. L. (2025) · Imaging Neuroscience · doi:10.1162/imag.a.936 · Cited by 3
SMARTs with treatment preference: Pragmatic SMART design and methods motivated by STAR*D
Medley, S., Wank, M., Tamura, R., Braun, T., & Kidwell, K. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108162 · Cited by 3
Metadata
- Authors
- Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- National University of Singapore (SG)
- Venue
- Psychiatric Services
- Published
- 2009-11
- Volume
- 60
- Issue
- 11
- Pages
- 1439-1445
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2095852687
- Cited by
- 661
- References
- 0
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 57 · 2023: 73 · 2022: 61 · 2021: 58 · 2020: 55 · 2019: 48 · 2018: 41 · 2017: 42 · 2016: 28 · 2015: 33 · 2014: 20 · 2013: 20 · 2012: 16
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- University of Texas Southwestern Medical Center
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- STAR*D, major depressive disorder, antidepressant treatment, treatment-resistant depression, remission, citalopram, antidepressant switching, antidepressant augmentation, primary care, psychiatric clinic
- MeSH terms
- Venlafaxine Hydrochloride, Adolescent, Adult, Aged, Cyclohexanols, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Primidone, Remission Induction, Time Factors, Citalopram, Cognitive Behavioral Therapy, Bupropion, Treatment Outcome, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Dopamine Uptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.